Clinical Trials Browser

Interventional × vadimezan × Tumor-Agnostic × Clear all

NCT01240642 2020-12-09

An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404

Phase 1 Terminated

Neoplasm Metastasis

NCT01278758 2020-12-09

A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function

Phase 1 Terminated

Neoplasm Metastasis

NCT01278849 2020-12-09

An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function

Phase 1 Terminated

Neoplasm Metastasis

NCT01299701 2017-02-14

A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors

Phase 1 Terminated

Neoplasm Metastasis

NCT01031212 2013-05-13

ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors

Phase 1 Withdrawn

Neoplasms

NCT01299415 2011-09-02

Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor

Phase 1 Terminated

Neoplasms

NCT00856336 2009-03-05

DART

Phase 1 Completed

Neoplasms